Amedeo Smart

Free Medical Literature Service


 

Amedeo

HIV Infection

  Free Subscription

Articles published in
Lancet Infect Dis
    October 2022
  1. BAGCCHI S
    Global alliance to tackle HIV in children.
    Lancet Infect Dis. 2022;22:1426.
    >> Share

    September 2022
  2. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    >> Share

  3. ONYEGBU C
    The persistence of HIV stigma in Kenya.
    Lancet Infect Dis. 2022;22:1292.
    >> Share

  4. BURKI T
    Involuntary sterilisation and HIV.
    Lancet Infect Dis. 2022;22:1284.
    >> Share

  5. MARX FM, Hesseling AC, Martinson N, Theron G, et al
    National survey in South Africa reveals high tuberculosis prevalence among previously treated people.
    Lancet Infect Dis. 2022;22:1273.
    >> Share

  6. LAPA D, Carletti F, Mazzotta V, Matusali G, et al
    Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding.
    Lancet Infect Dis. 2022;22:1267-1269.
    >> Share

    August 2022
  7. RAJASINGHAM R, Govender NP, Jordan A, Loyse A, et al
    The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.
    Lancet Infect Dis. 2022 Aug 29. pii: S1473-3099(22)00499.
    >> Share

  8. ZHAO FH, Wu T, Hu YM, Wei LH, et al
    Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.
    Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00435.
    >> Share

  9. SCHWARTZ NG, Hernandez-Romieu AC, Annambhotla P, Filardo TD, et al
    Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report.
    Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00425.
    >> Share

  10. NAZARETH J, Pan D, Martin CA, Barr I, et al
    Is the UK prepared for seasonal influenza in 2022-23 and beyond?
    Lancet Infect Dis. 2022 Aug 3. pii: S1473-3099(22)00503.
    >> Share

  11. BURKI T
    Guidelines for visceral leishmaniasis and HIV co-infection.
    Lancet Infect Dis. 2022;22:1124-1125.
    >> Share

  12. PETERS RPH, Chico RM, Rowley J, Low N, et al
    Estimating the global burden of sexually transmitted infections.
    Lancet Infect Dis. 2022;22:1112-1113.
    >> Share

  13. THE LANCET INFECTIOUS DISEASES
    Reaching the vulnerable without stigma.
    Lancet Infect Dis. 2022;22:1091.
    >> Share

  14. AYLES H, Mureithi L, Simwinga M
    The state of tuberculosis in South Africa: what does the first national tuberculosis prevalence survey teach us?
    Lancet Infect Dis. 2022;22:1094-1096.
    >> Share

    July 2022
  15. HENTZIEN M, Autran B, Piroth L, Yazdanpanah Y, et al
    A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab.
    Lancet Infect Dis. 2022 Jul 18. pii: S1473-3099(22)00495.
    >> Share

  16. CHARLES H, Prochazka M, Thorley K, Crewdson A, et al
    Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021-22: a descriptive epidemiological study.
    Lancet Infect Dis. 2022 Jul 6. pii: S1473-3099(22)00370.
    >> Share

  17. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
    Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
    >> Share

  18. GIROMETTI N, Byrne R, Bracchi M, Heskin J, et al
    Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis.
    Lancet Infect Dis. 2022 Jul 1. pii: S1473-3099(22)00411.
    >> Share

    June 2022
  19. COTTON MF, Madhi SA, Luabeya AK, Tameris M, et al
    Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.
    Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00222.
    >> Share

  20. TEMFACK E, Lortholary O
    Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa.
    Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00315.
    >> Share

  21. MASHAU RC, Meiring ST, Quan VC, Nel J, et al
    Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
    Lancet Infect Dis. 2022 Jun 21. pii: S1473-3099(22)00234.
    >> Share

  22. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
    Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
    Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
    >> Share

    May 2022
  23. CANNON C, Celum C
    Sexually transmissible infection incidence in men who have sex with men using HIV pre-exposure prophylaxis in Australia.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00284.
    >> Share

  24. TRAEGER MW, Guy R, Asselin J, Patel P, et al
    Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
    >> Share

  25. SEGERAL O, Dim B, Durier C, Nhoueng S, et al
    Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
    Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00206.
    >> Share

  26. MOYO S, Ismail F, Van der Walt M, Ismail N, et al
    Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017-19: a multistage, cluster-based, cross-sectional survey.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00149.
    >> Share

  27. LO NC, Bezerra FSM, Colley DG, Fleming FM, et al
    Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.
    Lancet Infect Dis. 2022 May 17. pii: S1473-3099(22)00221.
    >> Share

  28. KELLY JD, Van Ryn C, Badio M, Fayiah T, et al
    Clinical sequelae among individuals with pauci-symptomatic or asymptomatic Ebola virus infection and unrecognised Ebola virus disease in Liberia: a longitudinal cohort study.
    Lancet Infect Dis. 2022 May 16. pii: S1473-3099(22)00127.
    >> Share

  29. NDJEKA N, Campbell JR, Meintjes G, Maartens G, et al
    Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
    Lancet Infect Dis. 2022 May 2. pii: S1473-3099(21)00811.
    >> Share

    April 2022
  30. STEED D, Collins J, Farris AB, Guarner J, et al
    Haemophagocytic lymphohistiocytosis associated with bartonella peliosis hepatis following kidney transplantation in a patient with HIV.
    Lancet Infect Dis. 2022 Apr 29. pii: S1473-3099(22)00276.
    >> Share

  31. YAN X, Jia Z, Zhang B
    Evaluating the risk compensation of HIV/AIDS prevention measures.
    Lancet Infect Dis. 2022;22:447-448.
    >> Share

    March 2022
  32. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
    SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
    Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
    >> Share

  33. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
    Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
    >> Share

  34. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
    World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
    Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
    >> Share

  35. MUSHTAQ A, Kazi F
    Updates in pre-exposure prophylaxis for HIV.
    Lancet Infect Dis. 2022;22:320.
    >> Share

  36. BAGCCHI S
    Mother-to-child transmission of HIV in Botswana.
    Lancet Infect Dis. 2022;22:319.
    >> Share

    February 2022
  37. NAIDOO K, Dookie N
    Can the GeneXpert MTB/XDR deliver on the promise of expanded, near-patient tuberculosis drug-susceptibility testing?
    Lancet Infect Dis. 2022 Feb 25. pii: S1473-3099(21)00613.
    >> Share

  38. DECROO T, van Deun A
    Implications of bedaquiline-resistant tuberculosis.
    Lancet Infect Dis. 2022;22:166-167.
    >> Share

    January 2022
  39. LANGE C, Bottger EC, Cambau E, Griffith DE, et al
    Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00586.
    >> Share

  40. SRIDHAR S, Joaquin A, Bonaparte MI, Bueso A, et al
    Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Lancet Infect Dis. 2022 Jan 25. pii: S1473-3099(21)00764.
    >> Share

  41. DE VRIES HJC, de Laat M, Jongen VW, Heijman T, et al
    Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.
    Lancet Infect Dis. 2022 Jan 19. pii: S1473-3099(21)00625.
    >> Share

  42. KIRBY T
    Long-acting injectable for HIV approved for use in the UK.
    Lancet Infect Dis. 2022;22:26.
    >> Share

    December 2021

  43. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    Lancet Infect Dis. 2021 Dec 23. pii: S1473-3099(21)00751.
    >> Share

  44. SAMARASEKERA U
    Minoo Mohraz-Iran's leader in HIV research.
    Lancet Infect Dis. 2021;21:1640.
    >> Share

  45. KIRBY T
    Philippa Musoke-stop mother-to-child HIV transmission.
    Lancet Infect Dis. 2021;21:1641.
    >> Share

    November 2021
  46. DAWSON Q
    Is violence the only option to obtain health for HIV prisoners?
    Lancet Infect Dis. 2021 Nov 30. pii: S1473-3099(21)00757.
    >> Share

  47. DHANA A, Hamada Y, Kengne AP, Kerkhoff AD, et al
    Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis.
    Lancet Infect Dis. 2021 Nov 17. pii: S1473-3099(21)00387.
    >> Share

  48. ISMAIL NA, Omar SV, Moultrie H, Bhyat Z, et al
    Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
    Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00470.
    >> Share

  49. GOLDSTONE SE, Giuliano AR, Palefsky JM, Lazcano-Ponce E, et al
    Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Lancet Infect Dis. 2021 Nov 12. pii: S1473-3099(21)00327.
    >> Share

    October 2021
  50. KRUTIKOV M, Faust L, Nikolayevskyy V, Hamada Y, et al
    The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-gamma release assays: a systematic review and meta-analysis.
    Lancet Infect Dis. 2021 Oct 1. pii: S1473-3099(21)00261.
    >> Share

    September 2021
  51. RULE R, Mitton B, Govender NP, Hoffmann D, et al
    Spinal epidural abscess caused by Aspergillus spp masquerading as spinal tuberculosis in a person with HIV.
    Lancet Infect Dis. 2021 Sep 29. pii: S1473-3099(20)30979.
    >> Share


  52. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019.
    Lancet Infect Dis. 2021 Sep 23. pii: S1473-3099(21)00449.
    >> Share

  53. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Addendum needed on COVID-19 travel study - Authors' reply.
    Lancet Infect Dis. 2021 Sep 15. pii: S1473-3099(21)00562.
    >> Share

  54. HO CS, Feng PI, Narita M, Stout JE, et al
    Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Sep 6. pii: S1473-3099(21)00145.
    >> Share

  55. KIRBY T
    Marta Lado-Ebola, HIV, sexual health and more.
    Lancet Infect Dis. 2021;21:1224.
    >> Share

    August 2021
  56. DAMHORST GL, Watts A, Hernandez-Romieu A, Mel N, et al
    Acanthamoeba castellanii encephalitis in a patient with AIDS: a case report and literature review.
    Lancet Infect Dis. 2021 Aug 27. pii: S1473-3099(20)30933.
    >> Share

  57. BURKI T
    Infected blood inquiry in the UK.
    Lancet Infect Dis. 2021;21:1078-1079.
    >> Share

    July 2021
  58. NAKKAZI E
    Uganda's Sexual Offences Bill-a step backwards.
    Lancet Infect Dis. 2021;21:920.
    >> Share

    June 2021
  59. KENYON G
    Hong Shang-leading HIV/AIDS research in China.
    Lancet Infect Dis. 2021;21:779.
    >> Share

  60. BURKI T
    HIV in the age of COVID-19.
    Lancet Infect Dis. 2021;21:774-775.
    >> Share

  61. VASAN S, Pitisuttithum P
    Vaccine development lessons between HIV and COVID-19.
    Lancet Infect Dis. 2021;21:759-761.
    >> Share

  62. KIRBY T
    Mario Poljak - Central Europe's pioneer in diagnostics.
    Lancet Infect Dis. 2021;21:780.
    >> Share

  63. SAMARASEKERA U
    Linda-Gail Bekker-a leader at the service of the world.
    Lancet Infect Dis. 2021;21:778.
    >> Share

  64. KAZI F, Mushtaq A
    Loretta Sweet Jemmott-a voice for the voiceless.
    Lancet Infect Dis. 2021;21:777.
    >> Share

    May 2021
  65. ARORA U, Garg P, Agarwal S, Nischal N, et al
    Complexities in the treatment of coinfection with HIV, hepatitis B, hepatitis C, and tuberculosis.
    Lancet Infect Dis. 2021 May 20. pii: S1473-3099(20)30765.
    >> Share

  66. DAL-RE R, Bekker LG, Gluud C, Holm S, et al
    Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities.
    Lancet Infect Dis. 2021 May 18. pii: S1473-3099(21)00263.
    >> Share

  67. CHALMERS RM, Alexander C
    Defining the diagnosis of cryptosporidiosis.
    Lancet Infect Dis. 2021;21:589-590.
    >> Share

  68. KAZI F, Mushtaq A
    CROI 2021.
    Lancet Infect Dis. 2021;21:606.
    >> Share

    April 2021
  69. CHAPPELL KJ, Mordant FL, Li Z, Wijesundara DK, et al
    Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Lancet Infect Dis. 2021 Apr 19. pii: S1473-3099(21)00200.
    >> Share

  70. STOTT KE, Loyse A, Jarvis JN, Alufandika M, et al
    Cryptococcal meningoencephalitis: time for action.
    Lancet Infect Dis. 2021 Apr 16. pii: S1473-3099(20)30771.
    >> Share

  71. SPINELLI MA, Rutherford G, Gandhi M
    Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply.
    Lancet Infect Dis. 2021 Apr 14. pii: S1473-3099(21)00210.
    >> Share

    March 2021
  72. EL HALABI J, Palmer N, McDuffie M, Golub JJ, et al
    Measuring health-care delays among privately insured patients with tuberculosis in the USA: an observational cohort study.
    Lancet Infect Dis. 2021 Mar 23. pii: S1473-3099(20)30732.
    >> Share

  73. KIANG MV, Chin ET, Huynh BQ, Chapman LAC, et al
    Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study.
    Lancet Infect Dis. 2021 Mar 22. pii: S1473-3099(21)00134.
    >> Share

  74. GUILAMO-RAMOS V, Thimm-Kaiser M, Benzekri A, Hidalgo A, et al
    Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks.
    Lancet Infect Dis. 2021 Mar 18. pii: S1473-3099(20)30983.
    >> Share

  75. VAN DIJCK C, Tsoumanis A, Rotsaert A, Vuylsteke B, et al
    Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.
    Lancet Infect Dis. 2021 Mar 4. pii: S1473-3099(20)30778.
    >> Share

  76. POZNIAK A, Meintjes G
    Raltegravir in patients with tuberculosis.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30937.
    >> Share

  77. DE CASTRO N, Marcy O, Chazallon C, Messou E, et al
    Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    Lancet Infect Dis. 2021 Mar 2. pii: S1473-3099(20)30869.
    >> Share

    February 2021
  78. DODD PJ, Yuen CM, Jayasooriya SM, van der Zalm MM, et al
    Quantifying the global number of tuberculosis survivors: a modelling study.
    Lancet Infect Dis. 2021 Feb 25. pii: S1473-3099(20)30919.
    >> Share

  79. SPINELLI MA, Glidden DV, Gennatas ED, Bielecki M, et al
    Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity.
    Lancet Infect Dis. 2021 Feb 22. pii: S1473-3099(20)30982.
    >> Share

  80. PRENTICE S, Nassanga B, Webb EL, Akello F, et al
    BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.
    Lancet Infect Dis. 2021 Feb 17. pii: S1473-3099(20)30653.
    >> Share

  81. INZAULE SC, Tessema SK, Kebede Y, Ogwell Ouma AE, et al
    Genomic-informed pathogen surveillance in Africa: opportunities and challenges.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30939.
    >> Share

  82. DOOLEY KE, Rosenkranz SL, Conradie F, Moran L, et al
    QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Lancet Infect Dis. 2021 Feb 12. pii: S1473-3099(20)30770.
    >> Share

  83. MAKONI M
    New tuberculosis tests and drugs remain out of reach.
    Lancet Infect Dis. 2021;21:174.
    >> Share

    January 2021
  84. SCRIBA TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, et al
    Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
    Lancet Infect Dis. 2021 Jan 25. pii: S1473-3099(20)30914.
    >> Share

    December 2020
  85. HENGEL B, Causer L, Matthews S, Smith K, et al
    A decentralised point-of-care testing model to address inequities in the COVID-19 response.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30859.
    >> Share

  86. SAMER C, Lacombe K, Calmy A
    Cyber harassment of female scientists will not be the new norm.
    Lancet Infect Dis. 2020 Dec 23. pii: S1473-3099(20)30944.
    >> Share

  87. POUSTCHI H, Darvishian M, Mohammadi Z, Shayanrad A, et al
    SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Lancet Infect Dis. 2020 Dec 15. pii: S1473-3099(20)30858.
    >> Share

  88. NKEREUWEM E, Togun T, Gomez MP, Szekely R, et al
    Comparing accuracy of lipoarabinomannan urine tests for diagnosis of pulmonary tuberculosis in children from four African countries: a cross-sectional study.
    Lancet Infect Dis. 2020 Dec 11. pii: S1473-3099(20)30598.
    >> Share

  89. HAMADA Y, Gupta RK, Matteelli A, Abubakar I, et al
    Predictive performance of interferon-gamma release assays and tuberculin skin tests.
    Lancet Infect Dis. 2020;20:1371-1372.
    >> Share

    November 2020
  90. KAZI F, Mushtaq A
    Primary care of patients with HIV.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30925.
    >> Share

  91. SHROUFI A, Chiller T, Jordan A, Denning DW, et al
    Ending deaths from HIV-related cryptococcal meningitis by 2030.
    Lancet Infect Dis. 2020 Nov 27. pii: S1473-3099(20)30909.
    >> Share

  92. KENYON C, Manoharan-Basil SS
    Macrolide consumption and resistance in Mycoplasma genitalium.
    Lancet Infect Dis. 2020;20:1235-1236.
    >> Share

    October 2020
  93. ETARD JF
    Immunity to Ebola virus: the full picture is being revealed.
    Lancet Infect Dis. 2020 Oct 13. pii: S1473-3099(20)30793.
    >> Share

  94. KIRBY T
    Evelina Tacconelli-two viruses, two wars.
    Lancet Infect Dis. 2020;20:1132.
    >> Share

    September 2020
  95. HIRONS A, Khoury G, Purcell DFJ
    Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent.
    Lancet Infect Dis. 2020 Sep 25. pii: S1473-3099(20)30328.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016